@drsarahsam Correct Those who refuse, citing burnout overloaded efficiency challenged, need to refer the p-consult not say wait.. And fix their practices !they are already under serving (many) patients
@krishnanendo Sympathies, Reality check Sadly people even doctors will always be undervalued compared to promise of machines and big corporate $ products. Fix the horrible product !!
Make it staff time and patient education friendly. The qual of US health data is a undebatable scandal.
@BarbaraHershey8 They could delegate and undertake their favorite social initiatives They are more effective and efficient than government. No criticism just the basic economic dynamics ( think Chicago School
@JAMAOnc Fifty years in the field multiple profoundly shocking examples This is a failure of the schools, radio -TV and minority foreign language foundations. In terms of easy solutions, add pharmacies to the list
@JAMAOnc Even more fundamental
A neglected an unappreciated need to know one’s family history not just cancer
One can really do something meaningful for oneself and one’s children and parents with the info
New online advanced resistant cholangiocarcinoma cca confirms years of added survival ( Frontiers)
A third series with cca and sixth form of cancer with exceptionally safe prolonged survival (Plos one Nov 2022
More clinical consulting with application of the Plos one methodology The findings of substantial safety and survival now confirmed for gynecological cancers and individual GI Cancer series’ prognostic features
Problem for publication which method or mechanism to prioritize?
@MDAndersonNews The message for caregivers, pain and poor quality of life are unacceptable usually not always avoidable Think prevention early intervention education treatment including the cancer, Prognosis and predictable survival, unknown to most,have changed big time
@BloodAdvances Absolutely appalling A huge difference missed for years
An argument for “big data AI” of all ICU data considering what an icu day costs and trend better outcomes ..data collection - analysis is a must..
ASCO 19,20 meetings add safety and prognostic tests to top feasible objectives. My colleagues are wrestling with how to present ASCO 20 ESMO 20 SIGO 19,20 objective prognostic tests that predict a majority of our patients can safely reach more long - survival milestones.
@cure_magazine My patients experience this over and over
Favorably reported obvious rational target basket drugs are $ unavailable The approval process is too slow for some targets orphan indications